Nusano
  • Company
    • Leadership
    • Mission & Values
    • West Valley City
    • Contact Us
  • Technology
  • Life Sciences
    • Medical Isotopes
    • Request Quote
    • R&D Collaboration
    • Advisory Board
    • About Nuclear Med
  • Energy
    • HALEU
    • Nuclear Fuel Cycle
  • Industrial
  • Batteries
  • News
    • Press Releases
    • Video
    • Podcast
  • Careers
    • Current Openings
    • Life in Utah
Select Page
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

by Scott Larrivee | Jun 19, 2025 | News

Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies  DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...

Recent Posts

  • Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall
  • Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
  • Nusano CEO Chris Lowe on Connor Group Podcast
  • dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
  • Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2025 Nusano | Web design
Privacy Policy – Terms of Service